Madsen Haker PLLC brings deep experience and expertise in complex financial and white-collar litigation, representing individuals and institutions in high-stakes civil and regulatory matters. The firm’s practice spans investigations, trials, and appeals, with a strategic, results-driven approach informed by a sophisticated understanding of financial markets and enforcement authorities.

Our representative matters include:

• Represented leading renewable energy company in U.S. Department of Justice (DOJ) and U.S. Securities and Exchange Commission (SEC) investigations regarding alleged federal securities law violations.
• Represented hedge fund analyst in an insider trading investigation and case filed by the SEC in the Southern District of New York.
• Counseled corporate executive on purported violations of securities laws, including Section 17(a) of the Securities Act, Section 10(b) of the Exchange Act and Rule 10b-5, stemming from disclosures related to a financing agreement.
• Represented executive of leading engineering firm in DOJ investigation regarding allegations of financial fraud.
• Represented investors in federal case relating to a Special Purpose Acquisition Company (SPAC) regarding breach of warrant agreement for acquisition of common stock.
• Obtained summary judgment on behalf of an investment firm in a dispute with a publicly-traded company regarding the breach of a convertible promissory note.
• Represented attorney in connection with DOJ and SEC investigations of attorney’s client for alleged securities fraud.
• Represented international accounting firm in regulatory investigations conducted by the SEC and the Public Company Accounting Oversight Board (PCAOB) concerning fee structures.
• Represented multiple investors asserting federal restitution claims in the Southern District of New York arising out of fraudulent SPAC vehicles.
• Defended individual in connection with claims of wire fraud, investment advisor fraud, and money laundering asserted by Chinese holding company.
• Represented international biopharmaceutical company in connection with internal and potential regulatory investigations relating to allegations of inflated sales and earnings reports.
• Represented investment bank in connection with claims asserted by institutional investors and other banks concerning multiple sales of securities and internal holdings.
• Represented hedge fund in connection with federal restitution claim asserted in the Southern District of New York based on claims of insider trading.